ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
Status:
Completed
Trial end date:
2018-12-13
Target enrollment:
Participant gender:
Summary
The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is
rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a
new triple therapy to treat H. pylori infection in dyspeptic patients against an active
comparator.